{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-23-000073","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.244599+00:00","generated_at":"2026-06-08T23:21:14.741274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Curis Q3 net loss $12.2M ($2.13/sh); cash $68.5M; emavusertib studies resume","bullets":["Net loss narrowed to $12.2M from $13.3M YoY; revenue unchanged at $2.8M from Erivedge royalties.","Cash, cash equivalents and investments total $68.5M; company expects funding into 2025.","Patient enrollment restarted in Phase 1/2 TakeAim Leukemia and Lymphoma emavusertib studies after partial clinical hold lift.","Plans to initiate triplet combo study of emavusertib with azacitidine and venetoclax in AML in Q4 2023.","Updated TakeAim Lymphoma data expected at ASH December 2023; leukemia data in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-23-000073","json":"https://secwatch.observer/filing/0001108205-23-000073.json","markdown":"https://secwatch.observer/filing/0001108205-23-000073.md","text":"https://secwatch.observer/filing/0001108205-23-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/0001108205-23-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/cris-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:21:14.741274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fea4d632df889a56ce065028f10aef6e0c8943f2","claim":"CURIS INC reported third quarter of 2023 results: revenue $2.8 million, net income $12.2 million, EPS $2.13.","evidence_excerpt":"to a net loss of $45.3 million or $9.82 per share on both a basic and diluted basis for the same period in 2022. Revenues for the third quarters of 2023 and 2022 were both $2.8 million. Revenues for both periods consist of royalty revenues from Genentech and Roche's sales of Erivedge®. Revenues for the nine months ended September 30, 2023 and 2022 were both","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/0001108205-23-000073-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"$2.8 million"},{"label":"Net income","value":"$12.2 million"},{"label":"EPS","value":"$2.13"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}